Literature DB >> 8763348

Reversal of multidrug resistance in acute myeloid leukaemia and other haematological malignancies.

P Sonneveld1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8763348     DOI: 10.1016/0959-8049(96)00054-8

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


× No keyword cloud information.
  6 in total

Review 1.  Diagnostics of multidrug resistance in cancer.

Authors:  G Szakács; K Jakab; F Antal; B Sarkadi
Journal:  Pathol Oncol Res       Date:  1998       Impact factor: 3.201

Review 2.  Classical multidrug resistance in acute myeloid leukaemia.

Authors:  E Paietta
Journal:  Med Oncol       Date:  1997-03       Impact factor: 3.064

3.  In vivo use of all-trans retinoic acid prior to induction chemotherapy improves complete remission rate and increases rhodamine 123 uptake in patients with de novo acute myeloid leukemia.

Authors:  C Ustün; M Beksac; K Dalva; H Koc; N Konuk; O Ilhan; M Ozcan; P Topcuoglu; D Sertkaya; M Hayran
Journal:  Med Oncol       Date:  2002       Impact factor: 3.064

4.  Effects of NorA inhibitors on in vitro antibacterial activities and postantibiotic effects of levofloxacin, ciprofloxacin, and norfloxacin in genetically related strains of Staphylococcus aureus.

Authors:  J R Aeschlimann; L D Dresser; G W Kaatz; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  1999-02       Impact factor: 5.191

5.  Phase II trial of dexverapamil and epirubicin in patients with non-responsive metastatic breast cancer.

Authors:  M Lehnert; K Mross; J Schueller; B Thuerlimann; N Kroeger; H Kupper
Journal:  Br J Cancer       Date:  1998-04       Impact factor: 7.640

6.  The expression of P-glycoprotein does influence the distribution of novel fluorescent compounds in solid tumour models.

Authors:  C Martin; J Walker; A Rothnie; R Callaghan
Journal:  Br J Cancer       Date:  2003-10-20       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.